Analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to post earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Intec Pharma’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.28). Intec Pharma reported earnings per share of ($0.28) in the same quarter last year, which indicates a positive year-over-year growth rate of 17.9%. The business is expected to report its next earnings report on Friday, November 8th.

According to Zacks, analysts expect that Intec Pharma will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($1.00) to ($0.89). For the next fiscal year, analysts expect that the business will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.45) to ($0.16). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last posted its earnings results on Friday, August 9th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02).

Several analysts have commented on NTEC shares. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Wednesday, October 16th. Maxim Group downgraded shares of Intec Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 22nd. Roth Capital downgraded shares of Intec Pharma from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $10.00 to $1.00 in a research report on Friday, October 11th. HC Wainwright downgraded shares of Intec Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Finally, ValuEngine raised shares of Intec Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $9.96.

NTEC stock remained flat at $$0.72 during trading hours on Monday. 279,200 shares of the company’s stock traded hands, compared to its average volume of 1,001,957. The stock has a market cap of $24.46 million, a P/E ratio of -0.51 and a beta of -0.01. Intec Pharma has a 12 month low of $0.41 and a 12 month high of $9.25. The stock has a 50 day moving average of $0.83 and a 200 day moving average of $3.15.

In other news, CEO Jeffrey A. Meckler acquired 100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average cost of $0.46 per share, with a total value of $46,000.00. Following the acquisition, the chief executive officer now owns 176,761 shares in the company, valued at $81,310.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have purchased 145,000 shares of company stock valued at $71,350. 3.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Intec Pharma by 25.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 729,193 shares of the biotechnology company’s stock worth $3,165,000 after buying an additional 150,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in Intec Pharma by 1,335.5% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 624,809 shares of the biotechnology company’s stock valued at $2,711,000 after purchasing an additional 581,283 shares during the last quarter. River & Mercantile Asset Management LLP acquired a new position in Intec Pharma during the 2nd quarter valued at $1,230,000. Renaissance Technologies LLC acquired a new position in Intec Pharma during the 2nd quarter valued at $593,000. Finally, Morgan Stanley raised its stake in Intec Pharma by 38.4% during the 2nd quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 22,715 shares during the last quarter. 35.49% of the stock is owned by institutional investors and hedge funds.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: What is a SEC Filing?

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.